Search

Author/Creator Lau, David C W

1. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Issue 10077 (8th April 2017)

Authors:
le Roux, Carel W; Astrup, Arne; Fujioka, Ken; Greenway, Frank; Lau, David C W; Van Gaal, Luc; Ortiz, Rafael Violante; Wilding, John P H; Skjøth, Trine V; Manning, Linda Shapiro; Pi-Sunyer, Xavier
Journal:
Lancet
Issue:
Volume 389:Issue 10077(2017)
Page Start:
1399
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Issue 10317 (11th December 2021)

Authors:
Lau, David C W; Erichsen, Lars; Francisco, Ann Marie; Satylganova, Altynai; le Roux, Carel W; McGowan, Barbara; Pedersen, Sue D; Pietiläinen, Kirsi H; Rubino, Domenica; Batterham, Rachel L
Journal:
Lancet
Issue:
Volume 398:Issue 10317(2021)
Page Start:
2160
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Issue 10286 (8th May 2021)

Authors:
Enebo, Lone B; Berthelsen, Kasper K; Kankam, Martin; Lund, Michael T; Rubino, Domenica M; Satylganova, Altynai; Lau, David C W
Journal:
Lancet
Issue:
Volume 397:Issue 10286(2021)
Page Start:
1736
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗